Published in J Clin Oncol on July 27, 2009
Survival of patients with newly diagnosed glioblastoma treated with radiation and temozolomide in research studies in the United States. Clin Cancer Res (2010) 3.56
The addition of bevacizumab to standard radiation therapy and temozolomide followed by bevacizumab, temozolomide, and irinotecan for newly diagnosed glioblastoma. Clin Cancer Res (2011) 1.64
Glutamate and the biology of gliomas. Glia (2010) 1.48
Pathway inhibition: emerging molecular targets for treating glioblastoma. Neuro Oncol (2011) 1.38
Current trends in targeted therapies for glioblastoma multiforme. Neurol Res Int (2012) 1.23
A multi-institution phase II study of poly-ICLC and radiotherapy with concurrent and adjuvant temozolomide in adults with newly diagnosed glioblastoma. Neuro Oncol (2010) 1.13
Controversies in the adjuvant therapy of high-grade gliomas. Oncologist (2011) 1.12
MGMT promoter methylation in gliomas-assessment by pyrosequencing and quantitative methylation-specific PCR. J Transl Med (2012) 1.03
Recent advancements in multimodality treatment of gliomas. Future Oncol (2011) 1.02
Personalized treatment strategies in glioblastoma: MGMT promoter methylation status. Onco Targets Ther (2013) 0.97
Glutamate transporters in the biology of malignant gliomas. Cell Mol Life Sci (2013) 0.90
Phase 2 trial of talampanel, a glutamate receptor inhibitor, for adults with recurrent malignant gliomas. Cancer (2010) 0.90
Overexpression of calcium-permeable glutamate receptors in glioblastoma derived brain tumor initiating cells. PLoS One (2012) 0.87
Unique biology of gliomas: challenges and opportunities. Trends Neurosci (2012) 0.87
Riluzole enhances ionizing radiation-induced cytotoxicity in human melanoma cells that ectopically express metabotropic glutamate receptor 1 in vitro and in vivo. Clin Cancer Res (2011) 0.87
Towards personalized therapy for patients with glioblastoma. Expert Rev Anticancer Ther (2011) 0.83
Seizures and gliomas - towards a single therapeutic approach. Nat Rev Neurol (2016) 0.83
A series of structurally novel heterotricyclic alpha-amino-3-hydroxyl-5-methyl-4-isoxazole-propionate receptor-selective antagonists. Br J Pharmacol (2010) 0.82
Role of Biomarkers in the Clinical Management of Glioblastomas: What are the Barriers and How Can We Overcome Them? Front Neurol (2013) 0.82
Comparison of clinical outcomes and genomic characteristics of single focus and multifocal glioblastoma. J Neurooncol (2014) 0.82
MGMT testing for glioma in clinical laboratories: discordance with methylation analyses prevents the implementation of routine immunohistochemistry. J Cancer Res Clin Oncol (2012) 0.82
The AMPAR Antagonist Perampanel Attenuates Traumatic Brain Injury Through Anti-Oxidative and Anti-Inflammatory Activity. Cell Mol Neurobiol (2016) 0.77
Increased expression of glutamate transporter GLT-1 in peritumoral tissue associated with prolonged survival and decreases in tumor growth in a rat model of experimental malignant glioma. J Neurosurg (2013) 0.77
Neuro-oncology: Glioblastoma--community adjusts to new standard of care. Nat Rev Neurol (2012) 0.76
Predicting the cell death responsiveness and sensitization of glioma cells to TRAIL and temozolomide. Oncotarget (2016) 0.75
Seizure response to perampanel in drug-resistant epilepsy with gliomas: early observations. J Neurooncol (2017) 0.75
Brain Tumor-Related Epilepsy: a Current Review of the Etiologic Basis and Diagnostic and Treatment Approaches. Curr Neurol Neurosci Rep (2017) 0.75
Imbalance of Ca2+ and K+ fluxes in C6 glioma cells after PDT measured with scanning ion-selective electrode technique. Lasers Med Sci (2014) 0.75
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med (2005) 74.55
MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med (2005) 29.65
Glutamate release promotes growth of malignant gliomas. Nat Med (2001) 3.67
The x(c)- cystine/glutamate antiporter: a potential target for therapy of cancer and other diseases. J Cell Physiol (2008) 3.05
Blockage of Ca(2+)-permeable AMPA receptors suppresses migration and induces apoptosis in human glioblastoma cells. Nat Med (2002) 2.61
Astrocyte elevated gene-1 activates cell survival pathways through PI3K-Akt signaling. Oncogene (2007) 2.51
Glioma cells release excitotoxic concentrations of glutamate. Cancer Res (1999) 2.34
Inhibition of cystine uptake disrupts the growth of primary brain tumors. J Neurosci (2005) 2.17
Autocrine glutamate signaling promotes glioma cell invasion. Cancer Res (2007) 2.03
Compromised glutamate transport in human glioma cells: reduction-mislocalization of sodium-dependent glutamate transporters and enhanced activity of cystine-glutamate exchange. J Neurosci (1999) 1.94
Modulation of glioma cell migration and invasion using Cl(-) and K(+) ion channel blockers. J Neurosci (1999) 1.89
Glutamate antagonists limit tumor growth. Proc Natl Acad Sci U S A (2001) 1.88
Molecular pharmacology of glutamate transporters, EAATs and VGLUTs. Brain Res Brain Res Rev (2004) 1.81
Astrocyte elevated gene-1: recent insights into a novel gene involved in tumor progression, metastasis and neurodegeneration. Pharmacol Ther (2007) 1.80
A role for glutamate in growth and invasion of primary brain tumors. J Neurochem (2008) 1.48
Ca2+-permeable AMPA receptors regulate growth of human glioblastoma via Akt activation. J Neurosci (2007) 1.35
Ion channels and amino acid transporters support the growth and invasion of primary brain tumors. Mol Neurobiol (2004) 1.21
Extracellular glutamate and other metabolites in and around RG2 rat glioma: an intracerebral microdialysis study. J Neurooncol (2000) 1.20
AMPA receptors promote perivascular glioma invasion via beta1 integrin-dependent adhesion to the extracellular matrix. Neuro Oncol (2008) 1.18
Talampanel. Neurotherapeutics (2007) 1.18
Phase 2 trial of copper depletion and penicillamine as antiangiogenesis therapy of glioblastoma. Neuro Oncol (2005) 1.16
Knockdown of GluR1 expression by RNA interference inhibits glioma proliferation. J Neurooncol (2008) 1.11
A crossover, add-on trial of talampanel in patients with refractory partial seizures. Neurology (2002) 1.10
Tetramethylpyrazine inhibits activities of glioma cells and glutamate neuro-excitotoxicity: potential therapeutic application for treatment of gliomas. Neuro Oncol (2008) 1.08
Survival of patients with newly diagnosed glioblastoma multiforme treated with RSR13 and radiotherapy: results of a phase II new approaches to brain tumor therapy CNS consortium safety and efficacy study. J Clin Oncol (2002) 0.96
A phase 1-2, prospective, double blind, randomized study of the safety and efficacy of Sulfasalazine for the treatment of progressing malignant gliomas: study protocol of [ISRCTN45828668]. BMC Cancer (2006) 0.91
Phase II clinical and pharmacologic study of radiation therapy and carboxyamido-triazole (CAI) in adults with newly diagnosed glioblastoma multiforme. Invest New Drugs (2006) 0.89
Suramin and radiotherapy in newly diagnosed glioblastoma: phase 2 NABTT CNS Consortium study. Neuro Oncol (2004) 0.89
Serum-dependence of AMPA receptor-mediated proliferation in glioma cells. Pathol Int (2006) 0.87
Effect of phenytoin on celecoxib pharmacokinetics in patients with glioblastoma. Neuro Oncol (2008) 0.86
Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines. Cancer Cell (2006) 15.16
Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol (2010) 14.79
Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol (2009) 14.15
The somatic genomic landscape of glioblastoma. Cell (2013) 11.73
A randomized trial comparing lung-volume-reduction surgery with medical therapy for severe emphysema. N Engl J Med (2003) 10.40
Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol (2008) 8.79
Neuronal and glioma-derived stem cell factor induces angiogenesis within the brain. Cancer Cell (2006) 8.09
Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma. Cancer Cell (2012) 6.71
DNA methylation markers and early recurrence in stage I lung cancer. N Engl J Med (2008) 5.87
Patients at high risk of death after lung-volume-reduction surgery. N Engl J Med (2001) 5.76
Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. N Engl J Med (2015) 5.71
Transforming fusions of FGFR and TACC genes in human glioblastoma. Science (2012) 5.09
American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer. J Clin Oncol (2009) 4.95
Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer. J Urol (2003) 4.66
An integrative approach for in silico glioma research. IEEE Trans Biomed Eng (2010) 4.55
Progression-free survival: an important end point in evaluating therapy for recurrent high-grade gliomas. Neuro Oncol (2008) 4.39
A Randomized Trial of Long-Term Oxygen for COPD with Moderate Desaturation. N Engl J Med (2016) 3.99
SSEA-1 is an enrichment marker for tumor-initiating cells in human glioblastoma. Cell Stem Cell (2009) 3.89
Epigenetic-mediated dysfunction of the bone morphogenetic protein pathway inhibits differentiation of glioblastoma-initiating cells. Cancer Cell (2008) 3.87
Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma. J Clin Oncol (2013) 3.81
Expression of Notch-1 and its ligands, Delta-like-1 and Jagged-1, is critical for glioma cell survival and proliferation. Cancer Res (2005) 3.63
Rembrandt: helping personalized medicine become a reality through integrative translational research. Mol Cancer Res (2009) 3.58
Survival of patients with newly diagnosed glioblastoma treated with radiation and temozolomide in research studies in the United States. Clin Cancer Res (2010) 3.56
Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme. J Clin Oncol (2008) 3.50
Phase I and correlative biology study of cilengitide in patients with recurrent malignant glioma. J Clin Oncol (2007) 3.29
Hypermethylation of CpG islands in primary and metastatic human prostate cancer. Cancer Res (2004) 3.29
A blinded, crossover study of the efficacy of the ketogenic diet. Epilepsia (2008) 3.28
2011 Focused Update of 2009 American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non-Small-Cell Lung Cancer. J Clin Oncol (2011) 3.21
Primary chemoprevention of familial adenomatous polyposis with sulindac. N Engl J Med (2002) 3.16
Intratumoral heterogeneity of receptor tyrosine kinases EGFR and PDGFRA amplification in glioblastoma defines subpopulations with distinct growth factor response. Proc Natl Acad Sci U S A (2012) 3.12
Screening for pancreatic neoplasia in high-risk individuals: an EUS-based approach. Clin Gastroenterol Hepatol (2004) 3.10
The integrated landscape of driver genomic alterations in glioblastoma. Nat Genet (2013) 2.89
Cognitive function over time in the Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT): results of a randomized, controlled trial of naproxen and celecoxib. Arch Neurol (2008) 2.86
Integrated morphologic analysis for the identification and characterization of disease subtypes. J Am Med Inform Assoc (2012) 2.68
Scale to predict survival after surgery for recurrent glioblastoma multiforme. J Clin Oncol (2010) 2.67
Differential sensitivity of glioma- versus lung cancer-specific EGFR mutations to EGFR kinase inhibitors. Cancer Discov (2012) 2.61
Immunosuppression in patients with high-grade gliomas treated with radiation and temozolomide. Clin Cancer Res (2011) 2.59
High-resolution global genomic survey of 178 gliomas reveals novel regions of copy number alteration and allelic imbalances. Cancer Res (2006) 2.56
A phase 2 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium study. Neuro Oncol (2006) 2.49
Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma. J Clin Oncol (2010) 2.45
Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08. Clin Cancer Res (2006) 2.44
Unsupervised analysis of transcriptomic profiles reveals six glioma subtypes. Cancer Res (2009) 2.42
Altered adenosine-to-inosine RNA editing in human cancer. Genome Res (2007) 2.38
Genomic changes and gene expression profiles reveal that established glioma cell lines are poorly representative of primary human gliomas. Mol Cancer Res (2008) 2.22
Spontaneous regression of high-grade cervical dysplasia: effects of human papillomavirus type and HLA phenotype. Clin Cancer Res (2005) 2.21
Glycogen synthase kinase-3 inhibition induces glioma cell death through c-MYC, nuclear factor-kappaB, and glucose regulation. Cancer Res (2008) 2.16
The role of whole brain radiation therapy in the management of newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline. J Neurooncol (2009) 2.13
Detection of 2-hydroxyglutarate in IDH-mutated glioma patients by in vivo spectral-editing and 2D correlation magnetic resonance spectroscopy. Sci Transl Med (2012) 2.12
Patterns of care and outcomes among elderly individuals with primary malignant astrocytoma. J Neurosurg (2008) 2.05
Phase 2 study of weekly irinotecan in adults with recurrent malignant glioma: final report of NABTT 97-11. Neuro Oncol (2004) 2.03
The induction of autophagy by gamma-radiation contributes to the radioresistance of glioma stem cells. Int J Cancer (2009) 1.98
The role of stereotactic radiosurgery in the management of patients with newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline. J Neurooncol (2009) 1.96
Neurocognitive function in patients with recurrent glioblastoma treated with bevacizumab. Neuro Oncol (2011) 1.95
Primary central nervous system lymphoma: time to ask the question. J Clin Oncol (2002) 1.92
Effect of brain- and tumor-derived connective tissue growth factor on glioma invasion. J Natl Cancer Inst (2011) 1.86
Neuronally expressed stem cell factor induces neural stem cell migration to areas of brain injury. J Clin Invest (2004) 1.85
Gene expression and angiotropism in primary CNS lymphoma. Blood (2006) 1.79
Phase I clinical and pharmacokinetic study of irinotecan in adults with recurrent malignant glioma. Clin Cancer Res (2003) 1.79
MR imaging predictors of molecular profile and survival: multi-institutional study of the TCGA glioblastoma data set. Radiology (2013) 1.77
Noninvasive MR imaging of magnetically labeled stem cells to directly identify neovasculature in a glioma model. Blood (2004) 1.76
Recognition of glioma stem cells by genetically modified T cells targeting EGFRvIII and development of adoptive cell therapy for glioma. Hum Gene Ther (2012) 1.75
Phase II, randomized, placebo-controlled trial of neoadjuvant celecoxib in men with clinically localized prostate cancer: evaluation of drug-specific biomarkers. J Clin Oncol (2009) 1.71
The role of surgical resection in the management of newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline. J Neurooncol (2009) 1.70
A phase II trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiforme postradiation therapy. Neuro Oncol (2009) 1.66
Secondary chemoprevention of Barrett's esophagus with celecoxib: results of a randomized trial. J Natl Cancer Inst (2007) 1.65
MicroRNA-137 is downregulated in glioblastoma and inhibits the stemness of glioma stem cells by targeting RTVP-1. Oncotarget (2013) 1.64
Cancer stem cells in gliomas: identifying and understanding the apex cell in cancer's hierarchy. Glia (2011) 1.63
Machine-based morphologic analysis of glioblastoma using whole-slide pathology images uncovers clinically relevant molecular correlates. PLoS One (2013) 1.62
History of allergies and autoimmune diseases and risk of brain tumors in adults. Int J Cancer (2002) 1.62
Predicting in vitro drug sensitivity using Random Forests. Bioinformatics (2010) 1.59
Cilengitide: an integrin-targeting arginine-glycine-aspartic acid peptide with promising activity for glioblastoma multiforme. Expert Opin Investig Drugs (2008) 1.56
Sham neurosurgical procedures in clinical trials for neurodegenerative diseases: scientific and ethical considerations. Lancet Neurol (2012) 1.54
Initial experience with bevacizumab treatment for biopsy confirmed cerebral radiation necrosis. J Neurooncol (2009) 1.54
Bevacizumab and irinotecan treatment for progressive diffuse brainstem glioma: case report. J Neurooncol (2009) 1.52
DNA repair gene polymorphisms and risk of adult meningioma, glioma, and acoustic neuroma. Neuro Oncol (2009) 1.51
Establishing percent resection and residual volume thresholds affecting survival and recurrence for patients with newly diagnosed intracranial glioblastoma. Neuro Oncol (2013) 1.51
Phase I/II trial of an allogeneic cellular immunotherapy in hormone-naïve prostate cancer. Clin Cancer Res (2006) 1.50
Reproductive and hormonal factors and risk of brain tumors in adult females. Int J Cancer (2005) 1.50
Is surgery at progression a prognostic marker for improved 6-month progression-free survival or overall survival for patients with recurrent glioblastoma? Neuro Oncol (2011) 1.50
Phase II trial of pazopanib (GW786034), an oral multi-targeted angiogenesis inhibitor, for adults with recurrent glioblastoma (North American Brain Tumor Consortium Study 06-02). Neuro Oncol (2010) 1.46
Correlations between magnetic resonance spectroscopy and image-guided histopathology, with special attention to radiation necrosis. Neurosurgery (2002) 1.45
A prognostic gene expression signature in infratentorial ependymoma. Acta Neuropathol (2012) 1.44
Primary CNS lymphoma of T-cell origin: a descriptive analysis from the international primary CNS lymphoma collaborative group. J Clin Oncol (2005) 1.44
Apparent diffusion coefficient histogram analysis stratifies progression-free and overall survival in patients with recurrent GBM treated with bevacizumab: a multi-center study. J Neurooncol (2012) 1.42
Oral valacyclovir as prophylaxis against herpes simplex virus reactivation during high dose chemotherapy for leukemia. Leuk Lymphoma (2004) 1.41